Contineum Therapeutics, Inc.

Direct answer

Contineum Therapeutics, Inc. is publicly traded on NASDAQ under the ticker CTNM.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic...

Can you invest in Contineum Therapeutics, Inc.?

Yes. Contineum Therapeutics, Inc. trades publicly on NASDAQ as CTNM.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Contineum Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.